SEOM–GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025)

• Josep Gumà ^[1] ; Natalia Palazón-Carrión ^[6] ; Antonio Rueda-Domínguez ^[7] ; Silvia Sequero ^[2] ; Virginia Calvo ^[3] ; Ramón García-Arroyo ^[8] ; José Gómez-Codina ^[9] ; Marta Llanos ^[4] ; Natividad Martínez-Banaclocha ^[5] ; Mariano Provencio ^[3]
  1. [1] Hospital Universitari Sant Joan de Reus

     Hospital Universitari Sant Joan de Reus

     Reus, España

     
  2. [2] Hospital Universitario San Cecilio

     Hospital Universitario San Cecilio

     Granada, España

     
  3. [3] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  4. [4] Hospital Universitario de Canarias

     Hospital Universitario de Canarias

     San Cristóbal de La Laguna, España

     
  5. [5] Instituto de Investigación Sanitaria y Biomédica de Alicante

     Instituto de Investigación Sanitaria y Biomédica de Alicante

     Alicante, España

     
  6. [6] Medical Oncology Department, Hospital Universitario, Virgen de la Macarena, Seville, Spain
  7. [7] UGCI Medical Oncology, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
  8. [8] Medical Oncology Department, Complejo Hospitalario Universitario, Pontevedra, Spain
  9. [9] Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 12, 2025, págs. 4381-4392
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological subtype of non-Hodgkin lymphoma and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hematopathologist is recommended to establish the diagnosis. Twenty years following its introduction, the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significantly improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The introduction of chimeric antigen receptor T cells, polatuzumab vedotin, tafasitamab, and cluster of differentiation (CD)20/CD3 bispecific antibodies is changing the natural history of patients with relapsed DLBCL and will challenge R-CHOP as the benchmark for newly diagnosed patients. These updated guidelines (2025) summarize current evidence and available therapies for the medical management of DLBCL.